Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC010841 | Panoply™ Human OLR1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC010841 | Panoply™ Human OLR1 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT0607 | Human OLR1 Knockout Cell Line-HeLa | Inquiry |
| CLOE-1313 | Human OLR1 HEK293 Cell Lysate | Inquiry |
| CLOE-2017 | Rat Olr1 (His) HEK293 Cell Lysate | Inquiry |
| CLOE-2019 | Rat Olr1 (Fc) HEK293 Cell Lysate | Inquiry |
| CLKO-0112 | OLR1 KO Cell Lysate-HeLa | Inquiry |
| CSC-SC010841-1 | Human OLR1 Stable Cell Line - HEK293 | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD11218Z | Human OLR1 adenoviral particles | Inquiry |
| LV20262L | human OLR1 (NM_001172633) lentivirus particles | Inquiry |
| LV20263L | human OLR1 (NM_002543) lentivirus particles | Inquiry |
| LV20264L | human OLR1 (NM_001172632) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH361668 | shRNA set against Human OLR1 (NM_002543.3) | Inquiry |
| SHH361672 | shRNA set against Mouse OLR1 (NM_138648.2) | Inquiry |
| SHH361676 | shRNA set against Rat OLR1 (NM_133306.2) | Inquiry |
| SHR050104 | shRNA set against Mouse Olr1(NM_138648.2) | Inquiry |
| SHR050208 | shRNA set against Human OLR1(NM_002543.3) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCB156861 | Rat OLR1 ORF clone (NM_133306.1) | Inquiry |
| CDCL143747 | Human OLR1 ORF clone (NM_001172633.1) | Inquiry |
| CDFH013097 | Human OLR1 cDNA Clone(NM_001172632.1) | Inquiry |
| CDFH013098 | Human OLR1 cDNA Clone(NM_001172633.1) | Inquiry |
| CDFH013100 | Human OLR1 cDNA Clone(NM_002543.3) | Inquiry |
| CDFL009708 | Mouse Olr1 cDNA Clone(NM_138648.2) | Inquiry |
| MiUTR1H-07058 | OLR1 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-08721 | OLR1 miRNA 3'UTR clone | Inquiry |
| SKO0052 | OLR1 Validated sgRNA vector | Inquiry |
| CDCB156712 | Cynomolgus OLR1 ORF clone | Inquiry |
| CDCB180249 | Rabbit OLR1 ORF clone (XM_008259641.1) | Inquiry |
| CDCL143745 | Mouse OLR1 ORF clone (NM_001172632.1) | Inquiry |
| CDCR266148 | Mouse Olr1 ORF Clone(NM_138648.2) | Inquiry |
| CDCR381013 | Rat Olr1 ORF Clone(NM_133306.2) | Inquiry |
| CDCS409009 | Human OLR1 ORF Clone (BC022295) | Inquiry |
OLR1, a lectin-like scavenger receptor, is highly conserved in mammals and it is capable of recognizing several ligands including the protein moiety of oxidized-LDL (ox-LDL), advanced glycation end-products, gram-positive and gram-negative bacteria and apoptotic cells. OLR1 is primarily expressed in vascular cells and vasculature-rich organs, and its activation by a wide range of stimuli indicative of dyslipidemia, inflammation and damage initiates several signaling cascades including MAPKs, other protein kinases as well as transcription factors NF-kB and AP-1.
Overexpression of OLR1 has been shown in cellular components of atherosclerotic lesions. Deletion of Olr1 in Ldlr knockout (KO) mice results in much smaller atherosclerotic lesions associated with a drastic reduction of inflammation in the aortic wall. Olr1 abrogation also attenuates angiotensin II-induced hypertension. Similarly, abrogation of Olr1 reduces the extent of ischemia/reperfusion injury.
Atherosclerosis is an inflammatory vascular disease accompanying with the occlusion of the arterial vessels. The early atherosclerotic lesions include sub-endothelial accumulations of lipid-engorged macrophages (foam cells), which are represented as ‘fatty streak’. Fatty streaks are not clinically harmful, but they can be the precursors of more advanced fibrous and plaque-type lesions characterized by the accumulation of lipid-rich necrotic debris and vascular smooth muscle cells (VSMCs). Like other scavenger receptors implicated in the atherosclerosis, the OLR1 mediated the OxLDL-induced NF-κB activation in VSMCs, which in turn augmented the ICAM-dependent monocyte adhesion onto the activated VSMCs. More striking finding is that the depletion or internalization of the OLR1 impaired the activation of PDGFRβ, a major growth factor receptor of VSMCs. This evidence suggests a novel function of OLR1 as a potential co-receptor for PDGFRβ, similar to a co-receptor neuropilin-1 for vascular endothelial growth factor receptor-2. Thus, it is likely that OLR1 is the first scavenger receptor that simultaneously coordinates the growth signaling and the inflammatory response in VSMCs (Figure 1). If this is the case, it is suspected that a PDGFR-targeted therapy against atherosclerosis and in-stent restenosis may cause a medical complication in hypercholesterolemia or hyperlipidemia patients.
Figure 1. OLR1 plays a dual receptor function in VSMCs .
An association between obesity and atherosclerotic disease states in humans is well established.
Associations with obesity have been found for various cancers, including breast and prostate neoplasms, suggesting a mechanistic overlap in the pathobiology of atherogenesis and tumorigenesis. Recently, Olr1, acting through NF-kB mediated inflammatory signaling, was strongly implicated in carcinogenesis. OLR1 locates within the area of chromosome 12p, which has been identified as the AD-susceptible region, and plays a role in lipid metabolism. Therefore, it has also been suggested to be a good candidate gene for Alzheimer’s disease (AD). Several SNPs within OLR1 have been reported to have association with AD among Caucasians.
References: